Published in J Med Chem on December 30, 2013
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J Am Chem Soc (2014) 1.23
Protein lysine acetylation by p300/CBP. Chem Rev (2015) 1.02
The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta (2014) 1.02
Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem (2015) 0.99
A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction. Angew Chem Int Ed Engl (2014) 0.88
Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. Sci Adv (2015) 0.86
9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem (2015) 0.84
Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nat Chem Biol (2016) 0.83
Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking. Biochemistry (2014) 0.78
Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. J Med Chem (2016) 0.77
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. Sci Adv (2016) 0.76
Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4. Sci Rep (2015) 0.76
Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology. Future Med Chem (2016) 0.76
Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development. Microbiol Mol Biol Rev (2017) 0.75
Structural features and inhibitors of bromodomains. Drug Discov Today Technol (2016) 0.75
LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Weinheim Bergstr Ger (2015) 0.75
Toward personalized management in bladder cancer: the promise of novel molecular taxonomy. Virchows Arch (2017) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr (2005) 29.38
Automated protein model building combined with iterative structure refinement. Nat Struct Biol (1999) 27.52
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr (2006) 14.21
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Cancer epigenetics: from mechanism to therapy. Cell (2012) 7.74
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene (2007) 3.19
Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins (1997) 3.02
Measurement of dynamic protein binding to chromatin in vivo, using photobleaching microscopy. Methods Enzymol (2004) 3.02
Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell (2013) 2.83
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Regulation of nucleosome dynamics by histone modifications. Nat Struct Mol Biol (2013) 2.71
Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res (2012) 1.73
Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem (2012) 1.64
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol Biosyst (2011) 1.58
Real-time and quantitative imaging of mammalian stress granules and processing bodies. Methods Enzymol (2008) 1.55
PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem (2011) 1.48
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J Med Chem (2012) 1.42
Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem (2012) 1.28
Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J Med Chem (2012) 1.23
From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg Med Chem Lett (2012) 1.11
Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem (2013) 1.09
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. J Med Chem (2004) 1.02
Naphthyl and coumarinyl biarylpiperazine derivatives as highly potent human beta-secretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem (2006) 0.80
Selective inhibition of BET bromodomains. Nature (2010) 18.79
Histone recognition and large-scale structural analysis of the human bromodomain family. Cell (2012) 5.15
Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci U S A (2006) 4.45
Protein production and purification. Nat Methods (2008) 3.97
Linear motif atlas for phosphorylation-dependent signaling. Sci Signal (2008) 3.77
Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell (2009) 3.51
Small-molecule inhibition of BRDT for male contraception. Cell (2012) 3.50
Crystal structure of the tetrameric Mad1-Mad2 core complex: implications of a 'safety belt' binding mechanism for the spindle checkpoint. EMBO J (2002) 3.42
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A (2007) 3.21
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J Biol Chem (2002) 2.95
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A (2006) 2.73
Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ (2016) 2.60
Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell (2008) 2.46
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J (2008) 2.36
Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem (2005) 2.34
Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure (2009) 2.33
The (un)targeted cancer kinome. Nat Chem Biol (2010) 2.33
Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation. Circ Res (2005) 2.32
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol (2010) 2.26
Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation. PLoS Biol (2010) 2.22
Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites. EMBO J (2008) 2.12
High-throughput production of human proteins for crystallization: the SGC experience. J Struct Biol (2010) 2.07
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol (2011) 2.06
Structure and substrate specificity of the Pim-1 kinase. J Biol Chem (2005) 1.96
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Specificity profiling of Pak kinases allows identification of novel phosphorylation sites. J Biol Chem (2007) 1.92
The bromodomain interaction module. FEBS Lett (2012) 1.92
The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens (2008) 1.91
Hsp70 chaperones as modulators of prion life cycle: novel effects of Ssa and Ssb on the Saccharomyces cerevisiae prion [PSI+]. Genetics (2004) 1.90
Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci U S A (2009) 1.85
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens (2008) 1.81
Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem (2012) 1.76
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice. J Leukoc Biol (2006) 1.73
Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J Med Chem (2012) 1.64
Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res (2007) 1.62
Construction of human activity-based phosphorylation networks. Mol Syst Biol (2013) 1.59
Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol Biosyst (2011) 1.58
Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A (2006) 1.57
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem (2012) 1.55
Disseminating structural genomics data to the public: from a data dump to an animated story. Trends Biochem Sci (2006) 1.55
Structures of ABCB10, a human ATP-binding cassette transporter in apo- and nucleotide-bound states. Proc Natl Acad Sci U S A (2013) 1.54
Ruthenium half-sandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed Engl (2006) 1.54
PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res (2013) 1.53
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med (2009) 1.52
Coupling PAF signaling to dynein regulation: structure of LIS1 in complex with PAF-acetylhydrolase. Neuron (2004) 1.51
UnPAKing the class differences among p21-activated kinases. Trends Biochem Sci (2008) 1.51
Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest (2009) 1.49
3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem (2011) 1.48
Effect of a glucose impulse on the CcpA regulon in Staphylococcus aureus. BMC Microbiol (2009) 1.46
Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem (2013) 1.46
Activation segment exchange: a common mechanism of kinase autophosphorylation? Trends Biochem Sci (2007) 1.45
Structure and regulation of the human Nek2 centrosomal kinase. J Biol Chem (2006) 1.45
SH2 domains: modulators of nonreceptor tyrosine kinase activity. Curr Opin Struct Biol (2009) 1.45
Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J Biol Chem (2012) 1.43
Structural and functional characterization of the human protein kinase ASK1. Structure (2007) 1.42
Physical capability scale: psychometric testing. Clin Nurs Res (2012) 1.38
Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure (2009) 1.36
Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure (2007) 1.35